​​​​​​​PsA Treatment Options Expand - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

​​​​​​​PsA Treatment Options Expand

Phase 3 POETYK trial results support FDA approval of deucravacitinib for adults with active PsA.

  • By

  • Kathryn Wighton

  • March 9, 2026

  • 3 min

Share

Objective:

To report on the FDA approval of deucravacitinib for the treatment of adults with active psoriatic arthritis.

Approach:
    Key Findings:
    • Deucravacitinib achieved ACR20 response in 54% of patients in both trials compared to 34% and 39% in placebo groups.
    • ACR50 responses were 24% vs 14% and 29% vs 16% for deucravacitinib vs placebo in the two trials respectively.
    • ACR70 responses were 12% vs 5% and 10% vs 5% for deucravacitinib vs placebo.
    • Minimal disease activity was achieved by a greater proportion of patients receiving deucravacitinib.
    Interpretation:

    Deucravacitinib is the first TYK2 inhibitor approved for psoriatic arthritis, showing significant efficacy in improving disease activity compared to placebo.

    Limitations:
    • The trials included only adults aged 18 years or older with active PsA.
    • POETYK PsA-1 participants had not previously received biologic DMARDs, while POETYK PsA-2 included patients with prior TNF inhibitor exposure.
    Conclusion:

    Deucravacitinib represents a new therapeutic option for adults with active psoriatic arthritis, demonstrating improved outcomes in clinical trials.

    Sources:

Original Source(s)

​​​​​​​PsA Treatment Options Expand

  • by Kathryn Wighton

  • March 9, 2026

Related Content

AI Scribes: Efficiency for Whom?

Unresolved safety, privacy, and regulatory concerns may limit benefits of AI scribes for physicians and patients.

GRAPPA, EULAR Criteria May Identify Complex PsA

Application of newly proposed GRAPPA and EULAR criteria in a longitudinal cohort identified progressively smaller groups of patients with early psoriatic arthritis who experienced persistently worse patient-reported outcomes.

Upadacitinib and Pain in RA, PsA

Mediation analysis suggests direct and indirect effects on pain reduction in rheumatoid and psoriatic arthritis.